首页> 美国卫生研究院文献>Clinical Psychopharmacology and Neuroscience >Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement
【2h】

Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement

机译:氯氮平在临床实践中的监测:超出强制性要求

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clozapine is effective in treatment resistant schizophrenia; however, it is underutilised probably because of its side effects. The side effects are also the potential reasons for clozapine discontinuation. A mandatory requirement for its use is regular monitoring of white blood cell count and absolute neutrophil count. However there are many side effects that need monitoring in clinical practice considering their seriousness. This article tries to summarise the clinical concerns surrounding the serious side effects of clozapine some of which are associated with fatalities and presents a comprehensive way to monitor patients on clozapine in clinical practice. It emphasizes the need to broaden the monitoring beyond the mandatory investigations. This may help in improving the safety in clinical practice and increasing clinician confidence for greater and appropriate use of this effective intervention.
机译:氯氮平可有效治疗精神分裂症。但是,它的未充分利用可能是由于其副作用。副作用也是氯氮平停药的潜在原因。使用它的强制性要求是定期监测白细胞计数和绝对中性粒细胞计数。然而,考虑到其严重性,在临床实践中有许多副作用需要监测。本文试图总结有关氯氮平严重副作用的临床关注,其中一些副作用与死亡相关,并提出了在临床实践中监测氯氮平患者的综合方法。它强调必须将监测范围扩大到强制性调查之外。这可能有助于提高临床实践的安全性,并增加临床医生对这种有效干预措施的更大和适当使用的信心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号